Combination therapy in epilepsy: when and what to use

Author(s): Kwan P, Brodie MJ


After being regarded as a last resort for over two decades, the role of combination therapy as a treatment strategy for epilepsy is undergoing re-evaluation. This is a result of the growing appreciation that all seizures cannot be controlled by monotherapy in a substantial proportion of patients, and of the development of a range of modern antiepileptic drugs (AEDs), some of which are better tolerated and less prone to complex pharmacokinetic drug interactions than their older counterparts.Robust evidence to guide clinicians on when and how to combine AEDs is lacking, and current practice recommendations are largely empirical. Monotherapy should remain the treatment of choice for newly diagnosed epilepsy. A combination of two AEDs can be considered after failure, resulting from lack of efficacy, of one or two different monotherapy regimens. A few patients will become seizure-free with a combination of three AEDs, but treatment with a combination of four or more is unlikely to be successful. There is some evidence to support a pharmacomechanistic approach to AED combination. Care should be taken to avoid excessive drug load, which is associated with increased toxicity. Bigger and better randomised, controlled studies are needed to determine the optimal time and way to combine AEDs.

Similar Articles

Early identification of refractory epilepsy

Author(s): Kwan P, Brodie MJ

Curing epilepsy: progress and future directions

Author(s): Jacobs MP, Leblanc GG, Brooks-Kayal A, Jensen FE, Lowenstein DH, et al.

The clinical impact of pharmacogenetics on the treatment of epilepsy

Author(s): Löscher W, Klotz U, Zimprich F, Schmidt D

Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy

Author(s): Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, et al.

Interaction of antiepileptic drugs with human P-glycoprotein in vitro

Author(s): Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE

The importance of drug interactions in epilepsy therapy

Author(s): Patsalos PN, Fröscher W, Pisani F, van Rijn CM

Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage

Author(s): Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, et al.

Nimodipine in refractory epilepsy: a placebo-controlled, add-on study

Author(s): Larkin JG, McKee PJ, Blacklaw J, Thompson GG, Morgan IC, et al.

Mechanisms of drug resistance

Author(s): Löscher W

The clinical impact of pharmacogenetics on the treatment of epilepsy

Author(s): Löscher W, Klotz U, Zimprich F, Schmidt D

Nimodipine as an add-on therapy for intractable epilepsy

Author(s): Meyer FB, Cascino GD, Whisnant JP, Sharbrough FW, Ivnik RJ, et al.